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ABSTRACT
Introduction: Patients with spontaneous
sub-arachnoid hemorrhage (SAH) might
develop various cardiac abnormalities,
however; the prognostic implications of these
cardiac abnormalities are not well known. This
study aimed to detect the cardiac abnormality
that correlates best with in-hospital all-cause
mortality in patients with SAH.
Methods: In this retrospective study, all
patients admitted to our institution with a
primary diagnosis of SAH, and underwent a
transthoracic echocardiogram (TTE) from July
2011 until May 2014, were enrolled. Data
gathered included patients’ demographics,
Hunt and Hess clinical grading, computed
tomography SAH Fisher grading, troponin T
level, electrocardiographic (ECG) changes, TTE,
and in-hospital all-cause mortality. Multivariate
logistic regression of the cardiac abnormalities
and in-hospital all-cause mortality was
performed.
Results: A total of 247 patients were included
in our analysis. In-hospital all-cause mortality
was 15.6% (38 patients). The presence of
elevated troponin T levels, resting segmental
wall motion abnormalities, reduced ejection
fraction (\35%), and prolonged corrected QT
interval (QTc) on ECG were associated with
increased in-hospital all-cause mortality on
univariate analysis. On multivariable
regression, QTc prolongation was the only
independent predictor for in-hospital all-cause
mortality (p = 0.04).
Conclusions: Prolonged QTc interval on ECG
was independently associated with in-hospital
all-cause mortality in patients presenting with
spontaneous SAH. Whether this is a causative
association or a marker of underlying severe
clinical presentation of SAH remains unknown.
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Sub-arachnoid hemorrhage (SAH) is associated
with a high mortality, particularly within the
first 48 h of presentation [1, 2]. Although
cardiac injury in SAH has been previously
described [3–5], the prognostic implications of
cardiac injury and its relationship with
short-term mortality remain controversial. In a
meta-analysis of 25 studies, there was a positive
association between various cardiovascular
abnormalities and mortality in SAH [6]. A few
studies illustrated an association and prognostic
significance of prolonged QTc in relation to
SAH morbidity and mortality [7, 8], while other
studies demonstrated that elevated troponin
level was associated with increased mortality
[9, 10]. A recent study suggested that resting
segmental wall motion abnormality (RSWMA)
was the only prognostic indicator of short-term
mortality, while other cardiovascular
abnormalities including QTc prolongation,
elevated troponins, or pro-brain natriuretic
peptide (BNP), were not significant on
multivariable regression analysis [11]. The aim
of our study was to further determine which
cardiovascular abnormalities in patients with




All patients with SAH admitted to the
University of Florida, a tertiary academic
hospital, from July 2011 until May 2014, using
International Statistical Classifications of
Diseases (ICD)-9 code 430, for identification of
SAH patients, were enrolled. As transthoracic
echocardiogram (TTE) findings were pertinent
to our study, only patients who had a TTE
performed during the admission were included.
TTE was identified by the Current Procedural
Terminology (CPT) code 93303. Patients
\18 years old, patients mislabeled as SAH, or
those with traumatic SAH were excluded from
the study. The diagnosis of spontaneous SAH
was confirmed by reviewing the computerized
tomography (CT) scan reports and the
admission documentation notes.
The following data were obtained: patients’
age, sex, history of hypertension, diabetes,
coronary artery disease, prior stroke, smoking
status, chronic kidney disease, baseline
Hunt-Hess score (from I to V) [12] and CT scan
Fisher grading for SAH (from 1 to 4) [13]. Based
on the heart rate measured on the first ECG
report, we categorized the patients’ rhythm
into: tachycardia ([100 bpm), normal
(60–100 bpm), and bradycardia (\60 bpm). A
prolonged QTc was defined as QTc interval
[450 ms in males and[470 ms in females [14].
Bazett’s formula was used to calculate the QTc
value from the report of first ECG performed
after admission [15]. ST elevation was defined as
elevation of [1 mm above the J-point in limb
leads and 2 mm in chest leads. Ejection fraction
was divided into: [55%, 35–55%, and \35%.
The presence and location of RSWMA, apical
ballooning, and global hypokinesis was also
recorded. A cardiologist, expert in cardiac
ultrasound, who was not directly involved in
the study, reported the TTE results. Highly
sensitive troponin T is the cardiac biomarker
of choice in our institution, with a reference
range of \0.03 ng/ml, thus 0.03 ng/ml and
above was considered as elevated troponin T
level. In-hospital mortality was confirmed by a
death note recorded by the physician at the
time of death. All study data were collected and
managed using REDCap electronic data capture
tools hosted at the University of Florida [16]. All
procedures followed were in accordance with
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the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
2013. The study protocol was approved by the
University of Florida Institutional Review
Board, which has waived the informed
consent given the retrospective nature of the
study.
Statistical Analysis
Descriptive statistics was performed for the
baseline demographics, ECG, TTE, troponin
levels, and in-hospital mortality. Data were
reported as frequencies for categorical
variables, as well as mean and standard
deviation for continuous variables. Logistic
regression with robust standard errors [17] for
the estimation of the odds ratio was performed
to identify the significant predictors of
in-hospital mortality. A final multivariate
model included the significant predictors of
in-hospital mortality. Results were reported as
odds ratio (OR), and corresponding 95%
confidence intervals (CI) for the cardiovascular
abnormalities. Data analysis was conducted
using SAS version 9.4 software (SAS Institute
Inc., Cary, NC, USA).
RESULTS
Baseline Characteristics
The study initially enrolled 2058 patients with
SAH, 295 of them had a TTE performed during
the hospitalization. Forty-nine patients had
either traumatic SAH or were mislabeled as
SAH and thus were excluded from the study. A
total of 244 patients were included in the final
analysis. The mean age was 59 years, with
two-thirds of the patients being females. The
majority of the patients had a clinical
(Hunt–Hess) grading of II–IV and a CT Fisher
grading of 2. In-hospital all-cause mortality was
15.6% of the patient population (Table 1).
Compared to the SAH survivors, the deceased
patients were older (p = 0.009), with a history of
coronary artery disease (p = 0.02), higher
Hunt-Hess grade (p\0.001), and higher
incidence of hydrocephalus (p = 0.021)
(Table 2).
Cardiac Biomarkers, ECG, and TTE
Findings
One hundred thirty-five patients had a troponin
level drawn, 37% of those patients had an
elevated troponin level during their admission
(50 patients), with a mean peak troponin value
of 0.15. Meanwhile, 193 patients had an ECG
performed during their stay; 78% of those had
an abnormal ECG finding (152 patients). The
commonest ECG abnormality was prolonged
QTc occurring in 57% (95 patients); 13% (26
patients) were found to have tachycardia.
Sixteen percent of the total patient population
(39 patients) had a RSWMA on TTE, and five
patients were found to have findings
compatible with takotsubo syndrome (Table 1).
Cardiovascular Predictors of in-Hospital
All-Cause Mortality
On univariate analysis, prolonged QTc
(p\0.005), elevated troponin level (p = 0.03),
EF\35% (p = 0.03), and RSWMA (p = 0.03)
were associated with an increased risk of
in-hospital all-cause mortality. However,
T-wave inversion (p = 0.12), ST elevation
(p = 0.22), and tachycardia (p = 0.24) were not
significantly associated with increased mortality
(Table 3). On multivariable regression analysis,
prolonged QTc was the only cardiac
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abnormality that was associated with increased
in-hospital mortality (OR 5.1, 95% CI
1.04–25.28, p = 0.04) (Table 4).
DISCUSSION
This retrospective analysis illustrates the
prognostic significance of prolonged QTc, in
relation to in-hospital all-cause mortality in
patients with spontaneous SAH. The presence of
prolonged QTc interval was associated with a
five-times-increased risk of death in SAH
patients, compared to those with normal QTc
interval. This concurs with the previous studies
that evaluated prolonged QTc interval
prognostic significance [7, 8]. Ichinomiya et al.
reached a conclusion similar to ours; however,
they used the Glasgow Outcome Scale at
hospital discharge, as a primary outcome,
rather than in-hospital mortality. They found
that a QTc of 448 ms at day 7 of admission was
73% sensitive (95% CI 68–78%) and 93%
specific (95% CI 90–96%) prognostic tool to
detect such outcome [7]. Marafioti et al.
reported that prolonged QTc was an
independent prognostic tool for detection of
index mortality in SAH patients when it was
Table 1 Patients’ characteristics, electrocardiographic,
echocardiographic, and cardiac biomarker abnormalities
Patient’s demographics Percentage*




Chronic kidney disease 3
Prior stroke 7
Prior coronary artery disease 17




























SD standard deviation, ICU intensive care unit, EF
ejection fraction, RSWMA resting segmental wall motion
abnormality
* Percentages are approximated to the nearest whole
number
** Percentages represent the number of patients who had
the procedure performed, not the total patient population
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compared to other prognostic risk factors such
as clinical and CT grading of SAH. Most of the
other cardiovascular abnormalities found in
SAH such as T-wave inversion, ST changes,
and RSWMA, were not reported in that
analysis [8].
This study was not designed to address the
pathophysiology behind prolonged QTc
association with increased short-term all-cause
mortality. However, the association might be
explained by either a causal relationship, where
prolonged QTc increases the chances of
developing ventricular arrhythmias and thus
sudden cardiac death [18], or the prolonged QTc
could be just a reflection of severe SAH grade,
which is associated with poor prognosis [7, 8]. A
Table 2 Demographic comparison of both dead and alive sub-arachnoid hemorrhage patients
Clinical presentation Dead patients (%) Alive patients (%) p value
Age, mean (SD) 64 (13) 58 (14) 0.009
Male 32 34 0.79
Diabetes 16 21 0.02
Hypertension 79 70 0.001




Current smoker 21 31
History of prior stroke 0 8.5 0.013
History of coronary artery disease 24 16 0.02











Hydrocephalus 78 56 0.021
All values are approximated to the nearest integer
SD standard deviation, CT computerized topography
* Values do not add to 100% due to missing data
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prospective study by Frontera et al. illustrated
the prognostic significance of arrhythmia
(including atrial fibrillation, atrial flutter, and
sustained ventricular tachycardia) in SAH
patients, showing an increased risk of
mortality compared to those with normal
heart rhythm (OR 8.0, 95% CI 1.9–34.0,
p = 0.005) [19].
In a multicenter prospective study by van der
Bilt, et al. [11], RSWMA was found to be the
only prognostic indicator of short-term
mortality, while other cardiovascular
abnormalities including QTc prolongation,
elevated troponins, or proBNP, lost their
significance on multivariable regression
analysis. Although our study reached a
different conclusion, multiple considerations
should be pointed out. First, that study
primarily enrolled patients with mild clinical
grading, and thus patients who might have the
highest risk of in-hospital mortality were
excluded. Also, it was not clear, from their
method, how the QTc interval was analyzed and
if it was incorporated in the multivariable
regression analysis or not. Finally, their
primary outcome was delayed cerebral
ischemia while mortality at 3 months was
reported as a secondary outcome, rather than
index hospitalization mortality.
Elevated troponin level increased the risk of
in-hospital death in our study by univariate
analysis; however, this risk lost its significance
after the multivariable regression analysis. This
observation concurs with some of the previous
studies [1, 11]. Meanwhile, studies reporting
elevated troponin as a prognostic risk factor for
mortality were not adjusted for other
cardiovascular abnormalities [10, 20]. In
addition, echocardiographic features of
takotsubo cardiomyopathy have been linked
to worse outcomes [21]; however, owing to the
small number of patients who had findings of
takotsubo syndrome (i.e., five patients), thus
our study could not confirm this association.
Limitations of our study include: first, as a
tertiary center we were more likely to have more
complex patients, compared to non-tertiary
hospital SAH population, however, no patients
were excluded because of severity of SAH.
Second, there were missing data regarding
some of the cardiovascular abnormalities
collected, including troponin levels and ECG
Table 3 Univariate analysis of the various cardiac








Hypertension 2.3 0.89–5.68 0.09
Heart rate[100 2.6 0.72–9.19 0.24
ST segment elevation 2.5 0.58–10.73 0.22
T-wave inversion 2.0 0.82–4.95 0.12
Prolonged QTc 5.4 1.77–16.29 \0.005
Elevated troponin 3.0 1.17–7.55 0.03
EF\35% 3.6 1.24–10.52 0.03
RSWMA 2.7 1.19–6.01 0.03
Global hypokinesis 2.9 0.50–16.28 0.23
QTc corrected QT interval, EF ejection fraction, RSWMA
resting segmental wall motion abnormality
* p value of less than 0.05 was considered to be statistically
signiﬁcant








RSWMA 0.8 0.19–3.55 0.79
Elevated troponin 2.8 0.75–10.10 0.13
EF\35% 1.5 0.49–4.54 0.48
Prolonged QTc 5.1 1.04–25.28 0.04
RSWMA resting segmental wall motion abnormality, EF
ejection fraction, QTc corrected QT interval
* p value of less than 0.05 was considered to be statistically
signiﬁcant
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reports; however, we do not believe that those
were not large enough to affect our final
analysis. Third, QTc interval was calculated by
computer, which used Bazett’s formula. Bazett’s
formula at best may be imprecise; however, it
remains the simplest and most applicable
formula for calculation of QTc [22]. Finally,
the confidence interval for prolonged QTc
association with in-hospital mortality is wide,
which might be due to our sample size, and thus
any conclusion drawn from our study needs to
be confirmed in a larger patient population.
CONCLUSIONS
Among the variable cardiac abnormalities seen in
patients with spontaneous SAH, prolonged QTc
interval on ECG was the only independent cardiac
predictor of in-hospital mortality. These data add
to the current literature regarding the cardiac
abnormalities to predict short-term all-cause
mortality in SAH patient population. Whether
this abnormality is a cause of SAH mortality or
simply a marker of severe underlying disease
remains an unanswered question.
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